sb 203580 has been researched along with miltefosine in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (miltefosine) | Trials (miltefosine) | Recent Studies (post-2010) (miltefosine) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 1,330 | 83 | 769 |
| Protein | Taxonomy | sb 203580 (IC50) | miltefosine (IC50) |
|---|---|---|---|
| RAC-alpha serine/threonine-protein kinase | Homo sapiens (human) | 9.6 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Laufer, S; Pillaiyar, T | 1 |
1 review(s) available for sb 203580 and miltefosine
| Article | Year |
|---|---|
Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Protein Kinase Inhibitors; SARS-CoV-2; Signal Transduction; Virus Replication | 2022 |